GlassScriptPhysician profile
Thomas C Callahan
NPI 1164861027
$11,108.18
in general payments reported to CMS, 2019-2025
51 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $1,185 · 2021: $1,527 · 2022: $1,111 · 2023: $4,027 · 2024: $1,160 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,262 · Travel and Lodging: $2,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,262.10 |
| Travel and Lodging | $2,973.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,240.17 | 2020-2024 | Aveir, Ensite Precision |
| Abbvie INC. | $1,309.62 | 2020-2025 | Ubrelvy, Vraylar, Viberzi |
| Astrazeneca Pharmaceuticals LP | $758.51 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $720.46 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Novartis Pharmaceuticals Corporation | $584.22 | 2019-2025 | |
| Pfizer INC. | $537.16 | 2019-2025 | |
| Novo Nordisk INC | $395.70 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $370.62 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $300.88 | 2019-2022 | |
| Allergan, INC. | $268.58 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $235.95 | 2019-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $211.11 | 2021-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $209.82 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $159.52 | 2019-2025 | |
| Amarin Pharma, INC. | $146.85 | 2020-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.